All In Biotech

Drug Trial Radar · NCT04680052

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 654 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

654

Actual

Start

Apr 15, 2021

Primary completion

Feb 23, 2024

Study completion Aug 9, 2028

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Dec 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.

Conditions

  • Follicular Lymphoma
  • Marginal Zone Lymphoma

Interventions

  • tafasitamabDrug

    tafasitamab will be administered IV for 12 cycles

  • rituximabDrug

    Rituximab will be administered IV on cycles 1 - 5

  • lenalidomideDrug

    Lenalidomide will be administered PO for 12 cycles

  • placeboDrug

    placebo will be administered IV for 12 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred FirstTime frame: up to approximately 34 months
  2. FL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred FirstTime frame: up to 2 years

Locations

261 sites in 28 countries. Site status is shown where the registry gives one.

  • John Muir Health Clinical Research Center

    Concord, California

  • Marin Cancer Care

    Greenbrae, California

  • The Oncology Institute of Hope and Innovation

    Pasadena, California

  • Sharp Memorial Hospital

    San Diego, California

  • Middlesex Hospital Cancer Center

    Middletown, Connecticut

  • Smilow Cancer Hospital

    New Haven, Connecticut

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Brcr Medical Center, Inc

    Plantation, Florida

  • Asclepes Research Centers

    Weeki Wachee, Florida

  • Northwest Georgia Oncology Centers,P.C

    Marietta, Georgia

  • Straub Medical Center

    Honolulu, Hawaii

  • Des Moines Oncology Research Association

    Des Moines, Iowa

  • Baptist Health Lexington

    Lexington, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • Tulane University

    New Orleans, Louisiana

  • University of Maryland-Greenebaum Cancer Center

    Baltimore, Maryland

  • Cancer Center For Blood Disorders

    Bethesda, Maryland

  • Barbara Ann Karmanos Cancer Hospital

    Detroit, Michigan

  • Metro-Minnesota Community Oncology Reserch Consortium (Mmcorc)

    Saint Louis Park, Minnesota

  • Hattiesburg Clinic Hematology

    Hattiesburg, Mississippi

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Nyu Clinical Cancer Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Integris Cancer Institute

    Oklahoma City, Oklahoma

  • Charleston Hematology Oncology Associates

    Charleston, South Carolina

  • Prisma Health Upstate

    Greenville, South Carolina

  • Prairie Lakes Health Care System, Inc.

    Watertown, South Dakota

  • Texas Oncology-Baylor Charles A. Sammons

    Dallas, Texas

  • The Center For Cancer and Blood Disorders

    Fort Worth, Texas

  • Lyndon B Johnson General Hospital

    Houston, Texas

  • Md Anderson Cancer Center

    Houston, Texas

  • Renovatio Clinical

    Spring, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • University of Virginia Medical Center

    Charlottesville, Virginia

  • Vista Oncology Inc Ps

    Olympia, Washington

  • Virginia Mason Medical Center

    Seattle, Washington

  • University of Washington-Seattle Cancer Care Alliance

    Seattle, Washington

  • Northwest Medical Specialties Pllc

    Tacoma, Washington

  • Eastern Health

    Box Hill, Australia

  • Royal Hobart Hospital

    Hobart, Australia

Showing 40 of 261 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.